Efficacy of melatonin for sleep disturbance in middle-aged primary insomnia: a double-blind, randomised clinical trial
- PMID: 33157425
- DOI: 10.1016/j.sleep.2020.10.018
Efficacy of melatonin for sleep disturbance in middle-aged primary insomnia: a double-blind, randomised clinical trial
Abstract
Background: The aim of this study was to determine the efficacy of exogenous melatonin supplementation for sleep disturbances in patients with middle-aged primary insomnia.
Methods: This is a randomized double-blind, placebo-controlled parallel study. Participants were recruited from Tianlin community, Xuhui district, Shanghai. Ninety-seven consecutive middle-aged patients with primary insomnia were randomized to receive 3 mg fast-release melatonin (n = 51) or placebo (n = 46) for four-weeks. Objective sleep parameters tested by overnight polysomnography, subjective sleep performance and daytime somnolence obtained from the Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI) and Epworth Sleepiness Scale (ESS) were obtained at baseline and after treatment. Treatment was taken daily 1 h before bedtime. Serious adverse events and side-effects were monitored.
Results: Melatonin supplementation significantly decreased early wake time [-30.63min (95% CI, -53.92 to -7.34); P = 0.001] and percentage of N2 sleep [-7.07% (95% CI, -13.47% to -0.68%); P = 0.031]. However, melatonin had no significant effect on other objective sleep parameters including sleep latency, sleep efficiency, wake during the sleep and percent of N1, N3 and REM sleep. Melatonin had no effect on insomnia symptoms and severity on the PSQI [1.53(95% CI, -0.55 to 3.61); p = 0.504]; ISI [0.81 (95% CI, -2.27 to 3.88); p = 0.165] and ESS [-0.83 (95% CI, -3.53 to 1.88); p = 0.147]. No serious adverse events were reported.
Conclusions: Melatonin supplementation over a four-week period is effective and safe in improving some aspects of objective sleep quality such as total sleep time, percentage of rapid eye movement and early morning wake time in middle-aged patients with insomnia.
Trial registration: Identifier: ChiCTR-TRC-13003997; Prospectively registered on 2 December 2013.
Keywords: Melatonin; Pittsburgh sleep quality index; Polysomnography; Primary insomnia; Randomized.
Copyright © 2020 Elsevier B.V. All rights reserved.
Similar articles
-
Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial.BMC Med. 2018 Jan 19;16(1):8. doi: 10.1186/s12916-017-0995-1. BMC Med. 2018. PMID: 29347988 Free PMC article. Clinical Trial.
-
Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial.PLoS Med. 2018 Jun 18;15(6):e1002587. doi: 10.1371/journal.pmed.1002587. eCollection 2018 Jun. PLoS Med. 2018. PMID: 29912983 Free PMC article. Clinical Trial.
-
Standardized Extract of Valeriana officinalis Improves Overall Sleep Quality in Human Subjects with Sleep Complaints: A Randomized, Double-Blind, Placebo-Controlled, Clinical Study.Adv Ther. 2024 Jan;41(1):246-261. doi: 10.1007/s12325-023-02708-6. Epub 2023 Oct 30. Adv Ther. 2024. PMID: 37899385 Free PMC article. Clinical Trial.
-
The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement.Sleep. 1998;21(1):52-68. Sleep. 1998. PMID: 9485533 Review.
-
Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials.Sleep Med. 2019 Oct;62:6-13. doi: 10.1016/j.sleep.2019.03.016. Epub 2019 Apr 6. Sleep Med. 2019. PMID: 31518944
Cited by
-
Role of Melatonin in the Management of Sleep and Circadian Disorders in the Context of Psychiatric Illness.Curr Psychiatry Rep. 2022 Nov;24(11):623-634. doi: 10.1007/s11920-022-01369-6. Epub 2022 Oct 13. Curr Psychiatry Rep. 2022. PMID: 36227449 Free PMC article. Review.
-
Prevalence and patterns of sleep-related melatonin usage among adults in Saudi Arabia: A self-reported cross-sectional national study.Saudi Pharm J. 2024 Oct;32(10):102166. doi: 10.1016/j.jsps.2024.102166. Epub 2024 Aug 26. Saudi Pharm J. 2024. PMID: 39290452 Free PMC article.
-
Melatonin supplementation: new insights into health and disease.Sleep Breath. 2025 Apr 25;29(2):169. doi: 10.1007/s11325-025-03331-1. Sleep Breath. 2025. PMID: 40278958 Review.
-
Assessing the Risk of Bias in Randomized Clinical Trials With Large Language Models.JAMA Netw Open. 2024 May 1;7(5):e2412687. doi: 10.1001/jamanetworkopen.2024.12687. JAMA Netw Open. 2024. PMID: 38776081 Free PMC article.
-
Treatment Modalities for Insomnia in Adults Aged 55 and Older: A Systematic Review of Literature from 2018 to 2023.Curr Sleep Med Rep. 2024 Jun;10(2):232-256. doi: 10.1007/s40675-024-00285-w. Epub 2024 Feb 21. Curr Sleep Med Rep. 2024. PMID: 39156226 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical